Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Metastatic Castration-Resistant Prostate Cancer|Metastatic Breast Cancer|Non-small Cell Lung Cancer|Advanced Solid Tumors
DRUG: CCS1477|DRUG: Abiraterone acetate|DRUG: Enzalutamide|DRUG: Darolutamide|DRUG: Olaparib|DRUG: Atezolizumab
Incidence of treatment-related adverse events, Treatment-related adverse events and serious adverse events, Up to 12 months|Laboratory assessments, Clinical chemistry and haematology assessments, Up to 12 months
PSA response, PSA response as defined by Prostate Cancer Clinical Trial Working Group 3 (PCWG-3), Up to 12 months|CTC response, CTC response defined as a change from unfavourable (five or more cells) at baseline to favourable (four or fewer cells) post treatment, Up to 12 months|Objective response rate (ORR), * malignant soft tissue response rate (Response Evaluation Criteria in Solid Tumours \[RECIST\] v1.1)
* metastatic bone disease status (PCWG-3 bone scan criteria), Up to 12 months|Radiological progression-free survival (rPFS), Defined as the time from start of treatment until objective disease progression as defined by RECIST 1.1 or PCWG-3 or death, Up to 12 months|AUC of CCS1477, Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477, Up to 30 days after first dose of CCS1477|Cmax of CCS1477, Maximum observed plasma concentration (Cmax) of CCS1477, Up to 30 days after first dose of CCS1477
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.